Immunotherapy plus chemotherapy for advanced hypopharyngeal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (penpulimab) with chemotherapy for people with advanced hypopharyngeal cancer that can still be removed with surgery. The goal is to see if this combination shrinks tumors and improves outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with advanced hypopharyngeal cancer that is considered operable.
- You have not had prior systemic treatment for advanced cancer, though you may have had earlier neoadjuvant or adjuvant therapy if it was at least 6 months ago and did not leave any residual disease.
- You have not been treated with PD-1/PD-L1 inhibitors (like pembrolizumab or nivolumab) or EGFR inhibitors before.
- You are in generally good health with adequate organ function (kidney, liver, blood counts).
- You do not have active autoimmune disease, active infections (like HIV or tuberculosis), or other serious uncontrolled conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests giving chemotherapy combined with an immunotherapy drug (finotonlimab) before surgery for locally advanced hypopharyngeal cancer. It aims to shrink the tumor enough to improve surgery outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (TP regimen) before surgery for hypopharyngeal cancer that is locally advanced but hasn't spread. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests whether giving a type of immunotherapy (PD-1 inhibitor) together with chemotherapy before surgery can help treat advanced laryngeal and hypopharyngeal squamous cell carcinoma. It aims to improve outcomes for patients whose cancer hasn't spread to distant organs.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
Hear when a new Head & Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.